Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5949588 | 0.91 | CHRM5 (0.52) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL42121 | 0.88 | CHRM5 (0.67) | CHRM5ADRA2CACHESIGMAR1SMN1; SMN2 | |
| SCHEMBL1264162 | 0.84 | NCF1 (0.45) | CHRM5ADRA2CACHEKCNH2 | |
| SCHEMBL2254261 | 0.80 | CHRM5 (0.56) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL2249609 | 0.80 | CHRM5 (0.62) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL18740713 | 0.80 | — | — | |
| SCHEMBL41997 | 0.78 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| Hydrochloric Acid SCHEMBL7331633 | 0.77 | CHRM5 (0.57) | CHRM5ADRA2CACHESCN1ASCN4A | |
| SCHEMBL9431697 | 0.75 | DRD2 (0.38) | DRD2HTR2A | |
| SCHEMBL2749984 | 0.75 | KCNH2 (0.41) | CHRM5ADRA2CACHEKCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | ALKAHEST, INC. | 2023-11-02 | — | — | US | claimed |
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | ALKAHEST INC. | 2023-10-05 | — | — | US | claimed |
| EP-3572400-B1 | EZH2 INHIBITOR AND USE THEREOF | TARAPEUTICS SCIENCE INC (CN) | 2023-10-04 | — | — | EP | claimed |
| EP-4164643-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | Alkahest, Inc. (US) | 2023-04-19 | — | — | EP | claimed |
| CN-115697334-A | Methods of improving retinal related disease outcomes using CCR3 inhibitors | 万能溶剂有限公司 | 2023-02-03 | — | — | CN | claimed |
| WO-2021252647-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | ALKAHEST INC. (US) | 2021-12-16 | — | — | WO | claimed |
| EP-3856195-A1 | METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED IMPAIRMENTS USING CCR3-INHIBITORS | Alkahest, Inc. (US) | 2021-08-04 | — | — | EP | claimed |
| CN-112789044-A | Methods and compositions for treating aging-related injuries using CCR 3-inhibitors | 万能溶剂有限公司 | 2021-05-11 | — | — | CN | claimed |
| US-20210106577-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2021-04-15 | — | — | US | claimed |
| EP-3694514-A1 | METHODS AND COMPOSITIONS FOR TREATING PRURITUS, XEROSIS, AND ASSOCIATED DISEASE USING CCR3-INHIBITORS | Alkahest, Inc. (US) | 2020-08-19 | — | — | EP | claimed |
| WO-2004037811-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | claimed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | claimed |
| EP-0791592-B1 | Azetidines | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | claimed |
| EP-0775132-B1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2001-03-28 | — | — | EP | claimed |
| US-5968923-A | ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | claimed |
| US-5741790-A | Azetidines | PFIZER INC. (US) | 1998-04-21 | — | — | US | claimed |
| EP-0791592-A2 | Azetidines | Pfizer Limited (GB) | 1997-08-27 | — | — | EP | claimed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | claimed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106577-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | CHRM5 2598/4885ADRA2C 2695/4885ACHE 4858/4885 |
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | CCR3, CCR1, CCRL2 | CHRM5 2876/4885ADRA2C 2662/4885ACHE 4533/4885 |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | CHRM5 2201/4885ADRA2C 1426/4885ACHE 2849/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | CHRM5 477/4885ADRA2C 80/4885ACHE 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.